• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by HUTCHMED (China) Limited

    4/7/25 6:04:47 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCM alert in real time by email
    6-K 1 tm2511057d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

    SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of April 2025

     

    Commission File Number: 001-37710

     

     

     

    HUTCHMED (CHINA) LIMITED

    (Translation of registrant’s name into English)

     

     

     

    48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

    (Address of principal executive offices)

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F  x             Form 40-F  o

     

     

     

     

     

    HUTCHMED (CHINA) LIMITED

     

    Form 6-K

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
         
    Exhibit 99.1   2024 Annual Report
    Exhibit 99.2   Announcement relating to 2024 annual report and notice of annual general meeting
    Exhibit 99.3   Notice of 2025 annual general meeting
    Exhibit 99.4   Circular of 2025 annual general meeting
    Exhibit 99.5   Form of proxy for holders of ordinary shares
    Exhibit 99.6   Depositary’s notice of annual general meeting
    Exhibit 99.7   Voting instruction form for holders of American depositary shares

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      HUTCHMED (CHINA) LIMITED
         
      By:   /s/ Johnny Cheng
      Name: Johnny Cheng
      Title: Chief Financial Officer

     

    Date: April 7, 2025

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $HCM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HCM

    DatePrice TargetRatingAnalyst
    11/24/2023Hold → Buy
    Deutsche Bank
    5/4/2022Buy → Hold
    Deutsche Bank
    9/22/2021$46.00Buy → Neutral
    Goldman
    8/3/2021$52.00Buy
    Jefferies
    More analyst ratings

    $HCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UPDATE - International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Thursday, May 15, 2025 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in China, Hong Kong, Philippines, Denmark, Germany, South Africa, Switzerland, Sweden, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live pr

      5/8/25 10:44:07 AM ET
      $BLTE
      $COE
      $HCM
      $IH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate
    • International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Thursday, May 15, 2025 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in China, Hong Kong, Philippines, Denmark, Germany, South Africa, Switzerland, Sweden, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live pr

      5/8/25 8:35:00 AM ET
      $BLTE
      $COE
      $HCM
      $IH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Other Consumer Services
      Real Estate
    • HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, fruquintinib and surufatinib, which will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2025, taking place on April 25-30, 2025 in Chicago, Illinois. Details of the presentations are as follows: Abstract titlePresenter / Lead authorPresentation detailsSPONSORED STUDIESTargeting KEAP1/NRF2 signaling sensitizes KRAS-driven NSCLC to KRAS inhibitorsXianwen Yang, HUTCHMED, Shanghai, Ch

      4/23/25 8:00:00 PM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCM
    SEC Filings

    See more
    • SEC Form 6-K filed by HUTCHMED (China) Limited

      6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

      4/24/25 6:05:09 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by HUTCHMED (China) Limited

      6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

      4/22/25 6:04:07 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by HUTCHMED (China) Limited

      6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

      4/7/25 6:04:47 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCM
    Financials

    Live finance-specific insights

    See more
    • HUTCHMED to Announce 2024 Final Results

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will take place at 8:00 am EDT / 12:00 pm GMT / 8:00 pm HKT on Wednesday, March 19, 2025. In addition to the usual English webcast, there will also be a Chin

      2/19/25 3:30:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

      — HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED's pipeline and core innovative medicines business — — Focused R&D investment includes HUTCHMED's proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 01, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces that it has entered into two agreements to divest its 45% equity interest in Shang

      1/1/25 5:46:43 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED to Announce 2024 Half-Year Financial Results

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English conference call and audio webcast will be held on Wednesday, July 31, 2024, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT /

      6/26/24 4:30:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCM
    Leadership Updates

    Live Leadership Updates

    See more
    • HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Mr Wong Tak Wai (Mr Alvin Wong) is appointed as an Independent Non-executive Director and a member of the Audit Committee of the Company with effect from March 6, 2025. Mr Wong has over 35 years of extensive experience in accounting, auditing and corporate finance. He has acted in a pivotal role in assisting companies with their stock exchange listings and has been instrumental in completing numerous mergers and acquisitions. After a distinguished career spanning more than three decades, Mr Wong retired as

      3/5/25 5:00:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024. Dr Hu has over 20 years of experience in the development of therapeutic antibodies, antibody-drug conjugates, and vaccines. Throughout her career, she has demonstrated strong leadership and innovative capabilities, leading various research and development initiatives. Dr Hu's expertise spans from early-stage discovery to clinical developme

      11/20/24 4:30:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

      HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces:- (a) the retirement of Mr Simon To from the position as Chairman and Executive Director, after 23 years with the Company; and (b) the appointment of Dr Dan Eldar as the new Chairman. Dr Eldar has been a Non-executive Director of the Company since 2016. He has more than 30 years of experience as a senior executive, leading global operations in biotechnology, healthcare, telecommunications and water. He is an executive director of Hutchison Water Israel E.P.C Ltd, an associate of CK Hutchison group, which

      5/17/24 10:00:00 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by HUTCHMED (China) Limited (Amendment)

      SC 13G/A - HUTCHMED (China) Ltd (0001648257) (Subject)

      2/13/23 3:54:30 PM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by HUTCHMED (China) Limited (Amendment)

      SC 13G/A - HUTCHMED (China) Ltd (0001648257) (Subject)

      2/11/22 11:19:49 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by HUTCHMED (China) Limited (Amendment)

      SC 13D/A - HUTCHMED (China) Ltd (0001648257) (Filed by)

      2/7/22 6:12:18 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HUTCHMED upgraded by Deutsche Bank

      Deutsche Bank upgraded HUTCHMED from Hold to Buy

      11/24/23 7:13:23 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED downgraded by Deutsche Bank

      Deutsche Bank downgraded HUTCHMED from Buy to Hold

      5/4/22 3:18:20 PM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HUTCHMED downgraded by Goldman with a new price target

      Goldman downgraded HUTCHMED from Buy to Neutral and set a new price target of $46.00

      9/22/21 7:15:24 AM ET
      $HCM
      Biotechnology: Pharmaceutical Preparations
      Health Care